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Abstract
Background: Tail vein injection under short anesthesia is the most commonly used route for administering
radiopharmaceuticals. However, the small caliber of the vein in rodents may lead to tracer extravasation and
thereby compromise quantitative accuracy of PET. We aimed to evaluate a method for correction of interstitial
radiotracer leakage in the context of pre-clinical therapeutic response assessment.
Methods: In two separate studies involving 16 nude rats, a model of human ovarian cancer was xenografted and
each was treated with a Phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor or used as a control.
Tracer injections were performed via the tail vein by a single operator. Two observers qualitatively evaluated the
resulting images and if appropriate drew a volume of interest (VOI) over the injection site to record extravasated
activities. Uncorrected and corrected tumors’ mean standardized uptake value (SUV)mean was computed (corrected
injected activity = calibrated activity − decay corrected residual syringe activity − decay corrected tail extravasated
activity). Molecular analyses were taken as a gold standard. The frequency and magnitude of extravasation were
analyzed, as well as the inter-observer agreement and the impact of the correction method on tumor uptake
quantification.
Results: Extravasation never exceeded 20 % of the injected dose but occurred in more than 50 % of injections. It
was independent of groups of animals and protocol time points with p values of 1.00 and 0.61, respectively, in the
first experiment and 0.47 and 0.13, respectively, in the second experiment. There was a good inter-observer
agreement for qualitative analysis (kappa = 0.72) and a moderate agreement when using quantitative analysis (ρc= 0.94).
In both experiments, there was significant difference between uncorrected and corrected SUVmean. Despite this
significant difference, mean percent differences between uncorrected and corrected SUVmean in the first and the
second experiments were -3.61 and -1.78, respectively. Concerning therapy assessment, in both experiments,
significant differences in median %SUVmean between control and treated groups were observed over all time
points with either uncorrected and corrected data (p < 0.05).
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Conclusions: Although extravasation is common and can be reproducibly corrected, this is probably not
required for validation of response to drugs that induce large SUV changes. However, further studies are required
to evaluate the impact of extravasation in situations where less marked metabolic responses are observed or
important extravasations occur.
Keywords: Small animal PET, Cancer research, Therapy assessment, Tail vein injection, Extravasation,
Quantification
Background
In cancer research, 18fluorodeoxyglucose small animal
positron emission tomography/computed tomography
(18FDG SA-PET/CT) is a recognized non-invasive tool
for in vivo assessment of therapeutic response to novel
therapies [1–4]. To this end, accurate quantitative values,
such as standardized uptake values (SUVs), are mandatory.
However, there are numerous confounding factors, includ-
ing the mode of tracer administration.
Tail vein injection (with or without an intravenous
catheter) under short anesthesia is the most commonly
used route for administering radiopharmaceuticals. The
small caliber of the vein in rodents may, however, pre-
dispose to tracer extravasation into the interstitium.
Other validated administration routes are available, in-
cluding retro-orbital and intraperitoneal injection [5, 6].
The main limitation of the first technique relates to re-
strictions imposed by many animal care committees.
The second type of injection has several advantages. It is
reproducible in longitudinal studies and can be performed
on conscious animals, thereby reducing stress levels. How-
ever, a risk of failure remains (intra-digestive injection,
[7, 8]), and it has not been validated in animals bearing in-
traperitoneal tumors in which peritoneal tracer absorption
could be impaired. Moreover, even though delayed images
(60 min) have been shown to be equivalent to intravenous
injection [9–11], retro-orbital and intraperitoneal injections
do not allow dynamic imaging [5].
Methods for measuring tail vein injection failure quanti-
tatively have been developed [12, 13]. As far as we know,
however, the impact of extravasation on quantitative mea-
sures of tumor uptake and whether these can be reliably
corrected by estimation of extravasated activity has not
been evaluated in rats. Therefore, we aimed to evaluate
the impact of such a correction method in the context of
therapeutic response assessment of a dual Phosphoinosi-
tide 3-kinase/mammalian target of rapamycin inhibitor
(BEZ-235) on a chemoresistant model of human ovarian
cancer xenografted in nude rats.
Methods
Animal model
The regional Ethics Committee granted approval to con-
duct this study (no. N/02-10-09/18/10-12). All procedures
performed in this study involving animals were in accord-
ance with the ethical standards of the regional research
committee and with the 1964 Helsinki Declaration and its
later amendments.
In two experiments, 16 4-week-old female nude rats
(Harlan Laboratories, Indianapolis, IN, USA) bearing
subcutaneous SKOV3 human ovarian tumors were used.
Ten rats were treated with BEZ-235, a dual Phosphoino-
sitide 3-kinase/mammalian target of rapamycin inhibitor
(Selleck Chemicals, Houston, TX, USA) from day 0 to
day 3, with treatment being discontinued on day 4. Six
rats were used as controls. Each animal had four tumors:
two in the shoulders and two in the upper thighs, pro-
viding 64 lesions for evaluation.
In the first experiment, five rats underwent PET
imaging on days 0, 3, and 7. This cohort consisted of
two groups: untreated controls (n = 2) and treated rats
(n = 3). A second cohort was treated at the same time
points and used for molecular analysis. In the second
experiment, a cohort of 11 animals, consisting of un-
treated controls (n = 7) and rats receiving BEZ-235 (n = 4),
was used for both PET imaging and molecular analysis.
For the latter aim, one rat each from the treated and un-
treated groups was sacrificed on days 0, 3, and 4, and all
remaining animals were sacrificed after the last PET
examination had been performed on day 5. For general
anesthesia, heated inhaled isoflurane was administered
with an anesthesia device dedicated to small animals
(Minerve, France).
Molecular analyses were performed in both experi-
ments, including cell proliferation assessment (Ki-67
immunostaining), and Phosphoinositide 3-kinase/mam-
malian target of rapamycin target expression studies (p4E-
BP1 immunostaining), which were taken as gold standards
for therapeutic assessment in the present work.
Cross-calibration
A cross-calibration among the SA-PET/CT system and
the dose calibrator was performed. A 10-MBq 18F-FDG
solution (as assessed by the dose calibrator) was used to
fill a vial of exact known volume, which resulted in a solu-
tion of known concentration. This solution was used to fill
a cylinder phantom that was scanned for 20 min on the
SA-PET/CT scanner. A large volume of interest (VOI)
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was used to determine the mean activity concentration as
assessed by the SA-PET/CT scanner. Cross-calibration
factors were then derived and used to synchronize counts/
measurements for the two pieces of equipment.
SA-PET/CT acquisitions, reconstructions, and analysis
Animals were kept fasting for 6 h. As detailed above,
SA-PET/CT (Inveon system, Siemens Medical Solution,
Knoxville, TN, USA) examinations were performed on
days 0, 3, and 7 in the first experiment and days 0, 3, 4,
and 5 in the second experiment. The same individual
(NA, with a 15-year experience in tail vein injection) per-
formed tracer injections. Injections were performed intra-
venously through the tail vein, under general anesthesia,
using a 29-gauge needle. Injected volume was always kept
below 0.4 mL. The average calibrated activities were
38 ± 7 and 39 ± 5 MBq with uptake times of 91 ± 8
and 105 ± 14 min following injection, respectively, for
the first and second experiments. Animals were imaged in
prone position with the tail positioned on their right side.
Reconstructions were performed using a NEMA NU 4-
Optimized Maximum A Posteriori (MAP) Reconstruction
[14] with scatter and attenuation corrections.
SA-PET/CT analysis
Intravenous injections were qualitatively evaluated from
reconstructed images. When the observer concluded
to the presence of extravasation, a three-dimensional
volume of interest (VOI) with a visually adapted iso-
contour was drawn over the tail injection site (Fig. 1).
Activity in the tail (Bq and Bq/cc) was recorded. Two
independent observers made these analyses to deter-
mine the inter-observer variability. The activity of tail
vein injection extravasation was corrected for decay
assuming that there was no interstitial absorption of
the tracer in the tail between the injection and the
imaging session. Corrected injected activity was calculated
by the following formula:
Corrected injected activity
¼ calibrated activity−decay corrected residual
syringe activity−decay corrected tail
extravasated activity
For therapeutic response assessment in each experi-
ment, a cylindrical VOI was drawn over each tumor. The
uncorrected and corrected mean pixel values were ex-
tracted for each VOI and SUVmean were computed as
follows, assuming a 1 g/mL density:
SUV ¼ tumor activity
Bq
mL
   body weight gð Þ
injected dose Bqð Þ
Data were processed with a dedicated Siemens station
(Inveon Research Workplace 2.2, Siemens Molecular Im-
aging, Knoxville, TN, USA).
Statistical analysis
These analyses aimed to determine (1) if tail vein ex-
travasation corrected data performed better than uncor-
rected data for predicting target inhibition and (2) if
Fig. 1 Representative images in animals with and without misinjection. Maximum intensity projection (MIP) visualization of the small animal positron
emission tomography/computed tomography (SA-PET/CT) reconstruction for a treated rat in the second experiment without tracer extravasation on
day 0 (a) and with tracer extravasation on day 3 (b). On day 3, a volume of interest (VOI) region was manually drawn and a visually adapted.
Isocontour was applied (displayed in green) to quantify and correct for tail vein extravasation. Yellow arrows show the subcutaneous tumors
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there was inter-observer variability in the tail vein injec-
tion correction process. Statistical analyses were per-
formed on a per-lesion basis without taking into account
intra-rat correlation. Fisher’s exact probability tests, with
the Freeman–Halton extension when necessary [15],
were performed to test if the occurrence of tail vein ex-
travasation was different according to groups (treated or
not) and protocol time points. Inter-observer agreement
was assessed by means of Cohen’s kappa coefficients
(qualitative analysis) and Lin’s concordance coefficient
(quantitative analysis). Tail vein activity measurements
(Bq) of observers A and B were compared using Bland–
Altman method comparisons. Wilcoxon tests and
Bland–Altman plots were used for paired comparisons
of corrected and uncorrected data amongst treated and
control groups. To assess the ability to discriminate be-
tween control and treated groups, relative SUVmean
values of day 0 for each group were compared over the
different time points (day 3, 4, 5, and 7), for corrected
and uncorrected data, using Mann–Whitney tests. For
each test, the alpha risk was set at 0.05. Statistical ana-
lysis, graphs, and plots were performed with GraphPad
Prism version 5.0 for Mac (GraphPad Software, La Jolla,
CA, USA; www.graphpad.com).
Results
Tail vein extravasation frequency and magnitude
Both observers recorded that extravasation was visible in
at least 50 % of injections. According to observer A, tail
vein extravasation occurred in 92.3 and 59.4 % of SA-
PET/CT examinations in the first and second experi-
ments, respectively. In the first experiment, the percent-
age of injected activity remaining in the tail vein never
exceeded 20 %, with a maximum of 16.9 % in a control
rat on day 0.
According to observer B, tail vein extravasation oc-
curred in 69.2 and 50.0 % of SA-PET/CT examinations
in the first and second experiments, respectively. The
maximum tail vein remaining activity was 14.8 % and
was observed in the same animal described above.
Ranges of tail vein extravasation activity values and
their frequency are described in Table 1 for both ob-
servers. As shown in Fig. 2, the extravasation rate was
independent of groups and protocol time points in the
first and second experiments.
Inter-observer variability for tail vein activity
measurement
Bland–Altman analysis is shown in Fig. 3 and was con-
ducted on all measurements of both experiments. This
analysis demonstrated that the mean difference between
tail vein activity measurements obtained by observer A
and B was 18 kBq with narrow 95 % confidence inter-
vals. Overall, there was a good inter-observer agreement
when using qualitative analysis with a kappa value of
0.72 (95 % confidence interval (CI) 0.52–0.92) and a
moderate agreement when using quantitative analysis
with ρc value of 0.94 (95 % CI 0.88–0.97). Discordant re-
sults between observers occurred in 23.1 and 21.9 % of
the first and second experiment SA-PET/CT examina-
tions, respectively. In all but one case, observer A, indi-
cated the presence of extravasation whereas observer B
did not. Discordant results related to cases of low
remaining activities in the tail, ranging from 0.04 to
0.73 % of theoretical injected activity.
As there was low inter-observer variability for tail vein
activity measurement, the following results were
assessed only for observer A, who identified more epi-
sodes of extravasation.
Comparison between uncorrected and corrected data
In each experiment, there was a significant difference
between uncorrected and corrected SUVmean values with
p values <0.0001 (Fig. 4a, c). Bland–Altman analyses
showed that mean percent differences between uncor-
rected and corrected SUVmean values in the first and sec-
ond experiments were −3.61 and −1.78, respectively
(Fig. 4b, d).
Impact of tail vein extravasation on assessment of
therapeutic response
Molecular analysis
On day 3, immunohistochemistry studies showed de-
creases in p4E-BP1 phosphorylation, a downstream
marker of mTOR activation in treated animals. On
days 4 and 5, Phosphoinositide 3-kinase/mammalian
target of rapamycin pathways exhibited partial recov-
ery with almost complete recovery by day 7. When
focusing on cell proliferation, Ki-67 staining was sta-
tistically and significantly lower in the treated group
as compared with controls on days 3, 4, and 5. By
day 7, there was no difference between control and
treated groups. These results were detailed in another
publication [16] and were used as the reference
standard in the present work.
Table 1 Frequency and ranges of tail vein extravasation activity
values
Percentage of injected dose remaining in
tail vein
[0–2] [2–5] [5–10] >10
Experiment 1 Observer A (n) 7 2 2 1
Observer B (n) 3 4 1 1
Experiment 2 Observer A (n) 11 3 5 0
Observer B (n) 7 5 3 1
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SA-PET analysis
Both corrected and uncorrected data showed significant
decreases in 18F-FDG uptake on day 3 in treated groups
in each experiment with a partial uptake recovery by day
5 (second experiment), which became more pronounced
on day 7 (first experiment). In both experiments, signifi-
cant differences in median %SUVmean values between
control and treated groups were observed across all
times points, either with corrected or uncorrected data.
It is also noteworthy that quartiles were almost similar
with corrected and uncorrected data (Fig. 5).
Discussion
Gaining venous access in animals can be challenging,
even for experienced researchers, leading to tracer ex-
travasation and potentially biased quantitative values.
The present study evaluated whether data corrected for
tail vein extravasation using a subtraction method per-
formed better than uncorrected data in predicting
Fig. 2 Frequency of tail vein extravasations depending on group and protocol time points. Panels a and b display the first experiment results
and panels c and d display the second experiment results. For groups and protocol time point studies, only data of observer A is used. Of note,
only three animals were scanned on day 7 because two treated rats had died from treatment toxicity
Fig. 3 Relationship between quantitative values recorded by
observers a and b. Tail vein activity measurements (kBq) were
compared using Bland–Altman plot. The first experiment data is
displayed in blue and the second experiment data in green
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therapy response in a large panel of animals in two
therapeutic response assessment protocols. The main
findings were that (1) tail vein extravasations occurred
frequently (in at least in 50 % of cases as assessed by
each observer across both experiments) and (2) that its
frequency was not linked to treatment, time point within
a given experiment, nor the cumulative number of
injections. One would have expected the treatment-
associated side effects, such as dehydration and cachexia,
as well as repetitive injections, to impact on the quality
of tail vein injections. Observed extravasation frequen-
cies ranged from 50 to 92.3 % within the experiments
described, which is much higher than those observed in
other publications, reaching 40 % at worst [12, 13, 17].
Fig. 4 Comparison of corrected and uncorrected SUVmean values. a, b Upper panels display the SUVmean values of the first experiment, and
c, d lower panels display the SUVmean values of the second experiment, as recorded by observer A. Data is shown as Tukey boxplots
(left panels, lines displaying median, 25th and 75th percentiles; cross represents the mean value) and Bland–Altman plots (right panels)
Fig. 5 Uncorrected and corrected quantitative values in two therapy assessment experiments. Standard uptake values (SUVmean) relative to day 0
(medians, quartiles and means (star) for control and treated groups across all times points for the first and second experiments with uncorrected
(a) and corrected (b) data. Quantitative values were extracted from observer A data. Legend for p values: ***p < 0.001, **p < 0.01, and *p < 0.05
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However, it is likely that these authors did not look for
extravasation with the same scrutiny. For example, in
the study of Groman et al. [12], the presence of a misinjec-
tion was considered only when it exceeded 10 % of the
injected dose (Table 2). This led to a more limited assess-
ment of the problem by not accounting for the smallest
extravasations. However, our results demonstrated that,
despite one observer identifying extravasation more fre-
quently, there was little inter-observer variability in quan-
tifying the amount of activity extravasated using the tail
vein correction process. These findings suggest that this
technique is reproducible.
Remaining activity in the tail was measured on in vivo
imaging data because a cross-calibration between the
SA-PET system and the dose calibrator was undertaken
and because we had previously shown that ex vivo
counting (taken as gold standards) and Inveon SA-PET/
CT data was well correlated [18]. Moreover, Vines et al.
had also previously shown an excellent correlation be-
tween in vivo imaging measurements and ex vivo
gamma-well counter data [13]. Based on the SUV for-
mulae, residual activity in the tail (equal to 16.9 % at
worst in the present study) resulted in an underestima-
tion of SUV values when uncorrected, as shown in Fig. 4.
Chang et al. showed similar results [17]. In the current
experiments, the molecular targeted therapy that was
tested induced a marked decrease in 18F-FDG uptake.
The median relative changes in the first and second exper-
iments for treated animals were −70.02 and −61.69 %, re-
spectively, using uncorrected data. Therefore, one could
argue that the bias induced by tail vein extravasation
would have a more pronounced impact when testing other
therapies by inducing subtle changes in 18F-FDG uptakes.
However, differences between control and treated groups
were less important on days 4 to 7, when the therapy had
been withdrawn, and there was still no difference be-
tween uncorrected and corrected data at these time
points. Also, the situation of important extravasa-
tions, that could occur when junior researchers with
little experience perform tail vein injection, or in the
case of treatments inducing major cachexia, may re-
quire correction for extravasation.
The technique used in the present study was based on
the assumption that there was no interstitial absorption
of the tracer in the tail between the injection and the im-
aging session. Groman et al. [12] found that the tracer
was retained at the injection site over an observation
period of 7 days, but they used a 20-nm colloidal reagent
tracer that had a higher steric hindrance than 18F-FDG.
To the best of our knowledge, there are no available
studies evaluating this phenomenon with 18F-FDG. Re-
garding the relatively short uptake period (<120 min),
lymphatic clearance was considered negligible in the
present study.
Finally, this study was performed in rats bearing tu-
mors, whereas the most frequently used animal model
in cancer research is the mouse. Given that we found
that a percentage of injected activity remained in the
tail (range 0.04–16.9 %) in the same or lower order
of magnitude than in other studies on mice, we are
confident that similar results would be expected with
mice (Table 2).
Conclusions
Despite the relatively high frequency of tail vein extrava-
sation, the low activity remaining in the tail vein
Table 2 Summary of the main studies that have evaluated tail vein extravasation
Vines et al. Chang et al. Groman et al.
Animal model Mice originally used for various
oncology studies
Human HCT116 colon cancer
xenografted nude mice
(female, Charles River Laboratory)
Albino mice (males, 15 to 20 g, Swiss
CD-1(ICR)BR, Charles River Laboratory)
Number of animals 50 12 30
Injection method In-house needle catheters 30-gauge
needles insert into 15 cm of





Tracer 18F-FDG 18F-FPP(RGD)2 Mixed of two reagents:
99mTc-EB1 and
colloid gold
Injected activity 2–9 MBq over 20–30 s 1.9–3.8 MBq -
Injected volume 170 μL 100 μL 100 μL of mixture
Misinjection frequency and
assessment
7/50 (14.0 %) 4/23 (17.4 %) 12/30 (40.0 %)
Intermediate or poor injection
based on qualitative assessment
Visual inspection Injection efficiency <90 % based on
quantitative assessment
Quantitative evaluation Mean %ID/g on tail ranging
from 2.4 to 28.4
Percentage-intended dose not
injected ranging from 0.5 to 9.1 %
Percentage-intended dose not injected
ranging from 12 to 63 %
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following extravasation (never higher than 20 % of the
injected dose) led to a negligible magnitude of error and
did not interfere with the cancer therapy assessment in
rats bearing subcutaneous tumors undergoing targeted
therapy. Assessment of therapeutic response using
data uncorrected for tail vein extravasation provided
similar results to those following correction. Nevertheless,
there was no inter-observer variability when quantifying
tail vein activity suggesting that the correction of data for
tail vein extravasation can be reproducibly performed and
may be important when assessing therapies inducing more
subtle SUV changes between groups or when important
extravasations occur.
Ethics
The regional Ethics Committee granted approval to
conduct this study (no. N/02-10-09/18/10-12). All
procedures performed in this study involving animals
were in accordance with the ethical standards of the
regional research committee and with the 1964 Helsinki
Declaration and its later amendments.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CL participated in the design of the study and its coordination, helped to
perform statistical analysis, and drafted the manuscript. AED performed the
statistical analysis. MB participated in the coordination of the study and in
animal handling. SD carried out the molecular biology analysis. NA
conceived of the study, participated in its design and coordination, and
helped to draft the manuscript.
Acknowledgments
Prof. Aide and Dr. Lasnon are indebted to Prof. Rodney Hicks, Peter
MacCallum Cancer Institute, East Melbourne, Australia, for his expert review
of the manuscript.
Sources of support
This work was supported by a grant from the French Ligue contre le cancer,
Comité du Calvados.
Author details
1BioTICLA unit, UMR INSERM 1199, François Baclesse Cancer Centre,
UNICAEN, Caen, France. 2Normandie University Caen, Caen, France.
3Biostatistics and Clinical Research Department, François Baclesse Cancer
Centre, Caen, France. 4Nuclear Medicine Department, Caen University
Hospital, Avenue Côte de Nacre, 14000 Caen, France.
Received: 13 August 2015 Accepted: 26 October 2015
References
1. Abourbeh G, Itamar B, Salnikov O, Beltsov S, Mishani E. Identifying erlotinib-
sensitive non-small cell lung carcinoma tumors in mice using
[(11)C]erlotinib PET. EJNMMI Res. 2015;5:4. doi:10.1186/s13550-014-0080-0.
2. Chapman DW, Jans HS, Ma I, Mercer JR, Wiebe LI, Wuest M, et al.
Detecting functional changes with [(18)F]FAZA in a renal cell carcinoma
mouse model following sunitinib therapy. EJNMMI Res. 2014;4(1):27.
doi:10.1186/s13550-014-0027-5.
3. Emonds KM, Swinnen JV, Lerut E, Koole M, Mortelmans L, Mottaghy FM.
Evaluation of androgen-induced effects on the uptake of [18F]FDG,
[11C]choline and [11C]acetate in an androgen-sensitive and androgen-
independent prostate cancer xenograft model. EJNMMI Res. 2013;3(1):31.
doi:10.1186/2191-219X-3-31.
4. Hovhannisyan N, Guillouet S, Fillesoye F, Dhilly M, Patin D, Galateau F, et al.
Evaluation of the specificity of [(18)F]fludarabine PET/CT in a xenograft
model of follicular lymphoma: comparison with [(18)F]FDG and impact of
rituximab therapy. EJNMMI Res. 2015;5:23. doi:10.1186/s13550-015-0101-7.
5. Nanni C, Pettinato C, Ambrosini V, Spinelli A, Trespidi S, Rubello D, et al.
Retro-orbital injection is an effective route for radiopharmaceutical
administration in mice during small-animal PET studies. Nucl Med Commun.
2007;28(7):547–53. doi:10.1097/MNM.0b013e3281fbd42b.
6. Steel CD, Stephens AL, Hahto SM, Singletary SJ, Ciavarra RP. Comparison of
the lateral tail vein and the retro-orbital venous sinus as routes of
intravenous drug delivery in a transgenic mouse model. Lab Anim (NY).
2008;37(1):26–32. doi:10.1038/laban0108-26.
7. Arioli V, Rossi E. Errors related to different techniques of intraperitoneal
injection in mice. Appl Microbiol. 1970;19(4):704–5.
8. Gaines Das R, North D. Implications of experimental technique for analysis
and interpretation of data from animal experiments: outliers and increased
variability resulting from failure of intraperitoneal injection procedures.
Lab Anim. 2007;41(3):312–20. doi:10.1258/002367707781282802.
9. Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, et al. Impact
of animal handling on the results of 18F-FDG PET studies in mice. J Nucl
Med. 2006;47(6):999–1006.
10. Schiffer WK, Mirrione MM, Dewey SL. Optimizing experimental protocols for
quantitative behavioral imaging with 18F-FDG in rodents. J Nucl Med.
2007;48(2):277–87.
11. Wong KP, Sha W, Zhang X, Huang SC. Effects of administration route,
dietary condition, and blood glucose level on kinetics and uptake of 18F-
FDG in mice. J Nucl Med. 2011;52(5):800–7. doi:10.2967/jnumed.110.085092.
12. Groman EV, Reinhardt CP. Method to quantify tail vein injection technique
in small animals. Contemp Top Lab Anim Sci. 2004;43(1):35–8.
13. Vines DC, Green DE, Kudo G, Keller H. Evaluation of mouse tail-vein
injections both qualitatively and quantitatively on small-animal PET tail
scans. J Nucl Med Technol. 2011;39(4):264–70. doi:10.2967/jnmt.111.090951.
14. Lasnon C, Dugue AE, Briand M, Blanc-Fournier C, Dutoit S, Louis MH, et al.
NEMA NU 4-Optimized Reconstructions for Therapy Assessment in Cancer
Research with the Inveon Small Animal PET/CT System. Mol Imaging Biol.
2015;17(3):403–12. doi:10.1007/s11307-014-0805-5.
15. Freeman GH, Halton JH. Note on an exact treatment of contingency,
goodness of fit and other problems of significance. Biometrika.
1951;38(1–2):141–9.
16. Lheureux S, Lecerf C, Briand M, Louis MH, Dutoit S, Jebahi A, et al.
(18)F-FDG is a surrogate marker of therapy response and tumor
recovery after drug withdrawal during treatment with a dual Phosphoinositide
3-kinase/mammalian target of rapamycin inhibitor in a preclinical model of
cisplatin-resistant ovarian cancer. Transl Oncol. 2013;6(5):586–95.
17. Chang E, Liu S, Gowrishankar G, Yaghoubi S, Wedgeworth JP, Chin F, et al.
Reproducibility study of [(18)F]FPP(RGD)2 uptake in murine models of
human tumor xenografts. Eur J Nucl Med Mol Imaging. 2011;38(4):722–30.
doi:10.1007/s00259-010-1672-1.
18. Lasnon C, Quak E, Briand M, Gu Z, Louis MH, Aide N. Contrast-enhanced
small-animal PET/CT in cancer research: strong improvement of
diagnostic accuracy without significant alteration of quantitative
accuracy and NEMA NU 4-2008 image quality parameters. EJNMMI Res.
2013;3(1):5. doi:10.1186/2191-219X-3-5.
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Lasnon et al. EJNMMI Research  (2015) 5:61 Page 8 of 8
